April 16, 2019 8:19am
Share pricing has been bottoming; it’s time for some of the oversold … not all!
News: CRISPR Therapeutics (CRSP +$0.38 pre-market) and Vertex Pharmaceuticals (VRTX) FDA have been granted Fast Track Designation for CTX001 for the treatment of transfusion-dependent beta thalassemia (TDT). CTX001 is an investigational, autologous, gene-edited hematopoietic stem cell therapy for patients suffering from severe hemoglobinopathies.
Pre-open indications: 4 BUYs, 1 SELL and 3 TRADEs
Should have been a subscriber, you would be reading this now ...!
Members only. Please login.